Clinical Trials on Akute Leukämie mehrdeutiger Abstammung

Total 4474 results

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
St. Jude Children's Research Hospital
Syndax Pharmaceuticals

Recruiting

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Leukemia of Ambiguous Lineage | Relapsed Acute Myeloid Leukemia

United States
GlaxoSmithKline

Terminated

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Leukaemia, Myelocytic, Acute

United States, Australia, Canada
Bruno C. Medeiros
National Cancer Institute (NCI)

Terminated

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditions

United States
The First Affiliated Hospital of Soochow University
Northern Jiangsu Province People's Hospital; The Second People's Hospital of... and other collaborators

Recruiting

Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia

Newly Diagnosed | Acute Monocytic Leukemia

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Institut Paoli-Calmettes
INATHERYS

Recruiting

Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03)

Acute Lymphoblastic Leukemia, in Relapse | Acute Myeloid Leukemia, in Relapse | Mixed Phenotype Acute Leukemia | Acute Lymphoblastic Leukemia Recurrent | Acute Myeloid Leukaemia Recurrent

France
Uma Borate

Recruiting

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With KMT2A Rearrangement | Acute Myeloid Leukemia With NPM1 Mutation

United States
National Cancer Institute (NCI)

Completed

Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Leukemia Cutis | Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Relapsed Acute Myeloid Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Study of Biomarkers in DNA Samples From Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Secondary Acute Myeloid Leukemia | Childhood Acute Myeloid Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditions

United States
Peking University People's Hospital
Beijing JD Biotech Co. LTD.

Recruiting

Off-the-shelf CD123 CAR-NK for R/R AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Xuzhou Medical University

Recruiting

Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Uma Borate
Sumitomo Pharma Oncology, Inc.

Completed

TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia

United States
Oryzon Genomics S.A.

Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
University Hospital, Antwerp

Recruiting

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

Belgium
Medical College of Wisconsin

Recruiting

Venetoclax to Augment Epigenetic Modification and Chemotherapy

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Acute Leukemia French Association

Completed

Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor (RETRO-CBF)

Acute Myeloblastic Leukemia Core Binding Factor

France
St. Jude Children's Research Hospital
AbbVie; Gateway for Cancer Research; Karyopharm Therapeutics Inc

Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous Lineage

United States
Northwestern University

Terminated

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Bone Marrow Samples From Patients With Acute Promyelocytic Leukemia

Adult Acute Promyelocytic Leukemia (M3) | Childhood Acute Promyelocytic Leukemia (M3) | Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) | Adult Acute Myeloid Leukemia

United States
Xuzhou Medical University

Recruiting

Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

China
National Cancer Institute (NCI)

Completed

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia

B-cell Adult Acute Lymphoblastic Leukemia | Acute Undifferentiated Leukemia | Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia | B-cell Childhood Acute Lymphoblastic Leukemia | L1 Childhood Acute Lymphoblastic Leukemia | L2 Childhood Acute Lymphoblastic Leukemia | T-cell... and other conditions

United States
University of Washington
National Cancer Institute (NCI)

Completed

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | Adult... and other conditions

United States
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute

Active, not recruiting

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

United States
Astellas Pharma Global Development, Inc.

Completed

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

United States
Menarini Group

Terminated

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia (ARMY)

Recurrent Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse

France, Germany, Italy, Spain, Belgium
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Therapy-Related Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | FLT3 Gene Mutation | Acute Promyelocytic Leukemia With PML-RARA | Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1

United States
National Cancer Institute (NCI)

Recruiting

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Kronos Bio

Terminated

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid Leukemia

United States, Spain
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
Georgetown University
National Heart, Lung, and Blood Institute (NHLBI); Jazz Pharmaceuticals

Recruiting

Phase IB/II of CPX-351 for Relapse Prevention in AML

Acute Myeloid Leukemia (AML) in Remission

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia Leukemia

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Promyelocytic Leukemia With PML-RARA

United States
National Cancer Institute (NCI)

Completed

Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia

Chronic Myelomonocytic Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic... and other conditions

United States
Peking University People's Hospital
Ministry of Science and Technology of the People´s Republic of China

Not yet recruiting

Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL (RIF)

Acute Promyelocytic Leukaemia
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia in Remission | Myelodysplastic Syndrome With Excess Blasts | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 and other conditions

United States, Israel, Peru
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
Stanford University

Terminated

Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML)

Leukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)

United States
University of Colorado, Denver
Karyopharm Therapeutics Inc

Recruiting

KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Approved for marketing

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Astellas Pharma Global Development, Inc.

Recruiting

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) | FLT3-mutated Acute Myeloid Leukemia

United States
Radboud University Medical Center
Dutch Cancer Society

Recruiting

Natural Killer-cell Therapy for Acute Myeloid Leukemia (NK4AML)

Acute Myeloid Leukemia Refractory | Acute Myeloid Leukemia, Relapsed, Adult

Netherlands
University of Pennsylvania

Recruiting

Lentivirally Redirected CD123 Autologous T Cells in AML

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, Refractory

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Acute Myeloid Leukemia With FLT3/ITD Mutation | Acute Myeloid Leukemia With Gene Mutations | FLT3 Tyrosine Kinase Domain Point Mutation

United States
Massachusetts General Hospital

Completed

Alisertib for Acute Myeloid Leukemia

Acute Myelogenous Leukemia

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
Merus N.V.

Active, not recruiting

MCLA-117 in Acute Myelogenous Leukemia

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States, Italy, Netherlands, Belgium, France

Clinical Trials on Akute Leukämie mehrdeutiger Abstammung

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations